Ikarian Capital’s Alto Neuroscience ANRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.3M Buy
482,338
+75,000
+18% +$2.25M 1.24% 20
2026
Q2
$10.7M Sell
407,338
-107,662
-21% -$2.49M 1.16% 26
2026
Q1
$11.6M Hold
515,000
– – 0.94% 27
2025
Q4
$9.17M Buy
515,000
+405,000
+368% +$5.1M 0.72% 38
2025
Q3
$442K Hold
110,000
– – 0.04% 140
2025
Q2
$242K Sell
110,000
-65,000
-37% -$155K 0.05% 107
2025
Q1
$378K Sell
175,000
-175,000
-50% -$626K 0.05% 122
2024
Q4
$1.48M Buy
+350,000
New +$2.18M 0.2% 92

Other funds holding ANRO

Ikarian Capital's ANRO Position: Q3 2026 in Review

Ikarian Capital increased its Alto Neuroscience (ANRO) stake by 18% in Q3 2026, buying an estimated $2.25M and bringing the position to 482,338 shares worth $12.3M. The position accounts for 1.24% of the portfolio, ranked #20.

Ikarian Capital first reported a position in ANRO in Q4 2024 and has held it in 8 quarters since. 128 funds tracked by Wall St. Rank hold ANRO as of Q3 2026.

  • Ikarian Capital held 482,338 shares of Alto Neuroscience worth $12.3M as of Q3 2026.
  • Ikarian Capital bought 75,000 Alto Neuroscience shares in Q3 2026, an estimated $2.25M.
  • Alto Neuroscience made up 1.24% of Ikarian Capital's portfolio in Q3 2026, its #20 holding.
  • Ikarian Capital first reported a position in Alto Neuroscience in Q4 2024 and has held it in 8 quarters since.
  • 128 funds tracked by Wall St. Rank held Alto Neuroscience as of Q3 2026.

Based on Ikarian Capital's 13F filing for Q3 2026, filed 16 Nov 2026.